Translational Cell Therapy for Cancer

When:  Dec 3, 2016 from 1:30 PM to 5:30 PM (PT)

Translational Cell Therapy for Cancer

December 3, 2016
1:30 – 5:30 p.m.
Moscone Center • San Francisco, California

Presented by the American Society for Cell Biology (ASCB) in collaboration with the Society for Immunotherapy of Cancer

This joint special interest subgroup was part of the 2016 ASCB Annual Meeting. It addressed the critical cellular players in cancer immunotherapy—antigen presenting cells and effector T cells—as well as therapeutic modulation for effective antitumor immunity. More specifically, the first session of the program discussed the role of antigen presenting cells in priming antitumor immunity and the skewing of the immune system by dendritic cells and myeloid cells. The second session, on effector T cells, covered chimeric antigen receptor (CAR) and T-cell receptor (TCR) enginnering, T-Cell function, translation, and road blocks to treatment. In the final session, attendees learned about various modifiers of antitumor activity, including radiation therapy, STING agonists, and chemotherapy and its impact on tumor cell PD-1 expression.

Program Co-Chairs

Lisa H. Butterfield, PhD – University of Pittsburgh
Daniel J. Powell, Jr., PhD University of Pennsylvania

Session I: The Antigen Presenting Cell

1:30 – 1:50 p.m. Priming Anti-Tumor Immunity
Zena Werb., MD – University of California, San Francisco
1:50 – 2:10 p.m. Dendritic Cells and Myeloid Cell Skewing 
Lawrence Fong, MD – University of California, San Francisco
2:10 – 2:30 p.m. Vaccines
Lisa H. Butterfield, PhD – University of Pittsburgh
2:30 – 2:40 p.m. Q & A
Session II: The Effector T cell
2:40 – 3:00 p.m. T-cell Function
Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre
3:00 – 3:25 p.m. CAR and TCR Engineering
Daniel J. Powell, Jr., PhD  – University of Pennsylvania
3:25 – 3:50 p.m. Translation and Road Blocks
Gwendolyn K. Binder-Scholl, PhD, RAC - Adaptimmune
3:50 – 4:00 p.m. Q & A
4:00 – 4:15 p.m. Break
Session III: Modifiers of Anti-Tumor Activity
4:15 – 4:45 p.m. Radiation Therapy and Chemotherapy
Yang-Xin Fu, MD, PhD – University of Texas Southwestern Medical Center
4:45 – 5:15 p.m. Immunotherapeutics to Modulate the Tumor Microenvironment
Hideho Okada, MD, PhD – University of California San Francisco
5:15 – 5:30 p.m. Q & A

For more information, click here.

Location

Moscone Center
San Francisco, CA